Robert Leerink

For Corporates
Analyzing Healthcare M&A Trends: Q1 2024 Insights
Healthcare M&A activity remained robust in the first quarter of 2024, with 29 transactions vs. 28 in 2023. Biopharma was the most active healthcare subsector, representing 45% of deal volume, while Services activity remained dampened despite notable transactions such as Novo Holdings’ acquisition of Catalent. We expect Biopharma M&A activity to remain robust as large pharmaceutical companies attempt to fill revenue and pipeline gaps via acquisitions of late- or commercial-stage companies. We expect pre-commercial biopharma companies to continue pursue strategic alternatives, including mergers, private company mergers and cash-out transactions as a result of the dynamic capital markets environment.
LEARN MORE
For Investors
Sectors
Insights
About
- Firm
- Careers
- News
- Contact
- Transactions

Team
Leadership
Robert Leerink

Robert Leerink is a Senior Managing Director and Head of Institutional Equities at Leerink Partners.

Rob has been with the Firm since its inception in 1995. Prior to joining Institutional Sales team in 2000, Rob led the Private Client Services group at the Firm. Prior to Leerink Partners, he worked in the Private Client Services division of Fechtor Detwiler.

Rob holds a B.A. from Babson College.

Partner With Us

Contact Us